Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

C Orkin; E DeJesus; M Ramgopal; G Crofoot; P Ruane; A LaMarca; A Mills; B Vandercam; J de Wet; J Rockstroh; A Lazzarin; B Rijnders; D Podzamczer; A Thalme; M Stoeckle; D Porter; HC Liu; A Cheng; E Quirk; D SenGupta; H Cao

doi:10.1016/S2352-3018(17)30031-0

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

C Orkin, E DeJesus, M Ramgopal, G Crofoot, P Ruane, A LaMarca, A Mills, B Vandercam, J de Wet, J Rockstroh, A Lazzarin, B Rijnders, D Podzamczer, A Thalme, M Stoeckle, D Porter, HC Liu, A Cheng, E Quirk, D SenGuptaH Cao

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Background Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate. Methods In this randomised, double-blind, multicentre, placebo-controlled, non-inferiority trial, HIV-1-infected adults were screened and enrolled at 119 hospitals in 11 countries in North America and Europe. Participants were virally suppressed (HIV-1 RNA

Original language	English
Pages (from-to)	e195-e204
Journal	The Lancet HIV
Volume	4
Issue number	5
DOIs	https://doi.org/10.1016/S2352-3018(17)30031-0
Publication status	Published - 2017

Access to Document

10.1016/S2352-3018(17)30031-0

http://www.scopus.com/inward/record.url?scp=85014113739&partnerID=8YFLogxK

Fingerprint

Dive into the research topics of 'Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study'. Together they form a unique fingerprint.

Cite this

Orkin, C., DeJesus, E., Ramgopal, M., Crofoot, G., Ruane, P., LaMarca, A., Mills, A., Vandercam, B., de Wet, J., Rockstroh, J., Lazzarin, A., Rijnders, B., Podzamczer, D., Thalme, A., Stoeckle, M., Porter, D., Liu, HC., Cheng, A., Quirk, E., ... Cao, H. (2017). Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. The Lancet HIV, 4(5), e195-e204. https://doi.org/10.1016/S2352-3018(17)30031-0

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. / Orkin, C; DeJesus, E; Ramgopal, M et al.

In: The Lancet HIV, Vol. 4, No. 5, 2017, p. e195-e204.

Research output: Contribution to journal › Article › peer-review

Orkin, C, DeJesus, E, Ramgopal, M, Crofoot, G, Ruane, P, LaMarca, A, Mills, A, Vandercam, B, de Wet, J, Rockstroh, J, Lazzarin, A, Rijnders, B, Podzamczer, D, Thalme, A, Stoeckle, M, Porter, D, Liu, HC, Cheng, A, Quirk, E, SenGupta, D & Cao, H 2017, 'Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study', The Lancet HIV, vol. 4, no. 5, pp. e195-e204. https://doi.org/10.1016/S2352-3018(17)30031-0

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. The Lancet HIV. 2017;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0

@article{469a0a0d2d3745f6bca5e9e465bbe755,

title = "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study",

abstract = "Background Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate. Methods In this randomised, double-blind, multicentre, placebo-controlled, non-inferiority trial, HIV-1-infected adults were screened and enrolled at 119 hospitals in 11 countries in North America and Europe. Participants were virally suppressed (HIV-1 RNA ",

author = "C Orkin and E DeJesus and M Ramgopal and G Crofoot and P Ruane and A LaMarca and A Mills and B Vandercam and {de Wet}, J and J Rockstroh and A Lazzarin and B Rijnders and D Podzamczer and A Thalme and M Stoeckle and D Porter and HC Liu and A Cheng and E Quirk and D SenGupta and H Cao",

year = "2017",

doi = "10.1016/S2352-3018(17)30031-0",

language = "English",

volume = "4",

pages = "e195--e204",

journal = "The Lancet HIV",

issn = "2352-3018",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

AU - Orkin, C

AU - DeJesus, E

AU - Ramgopal, M

AU - Crofoot, G

AU - Ruane, P

AU - LaMarca, A

AU - Mills, A

AU - Vandercam, B

AU - de Wet, J

AU - Rockstroh, J

AU - Lazzarin, A

AU - Rijnders, B

AU - Podzamczer, D

AU - Thalme, A

AU - Stoeckle, M

AU - Porter, D

AU - Liu, HC

AU - Cheng, A

AU - Quirk, E

AU - SenGupta, D

AU - Cao, H

PY - 2017

Y1 - 2017

N2 - Background Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate. Methods In this randomised, double-blind, multicentre, placebo-controlled, non-inferiority trial, HIV-1-infected adults were screened and enrolled at 119 hospitals in 11 countries in North America and Europe. Participants were virally suppressed (HIV-1 RNA

AB - Background Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate. Methods In this randomised, double-blind, multicentre, placebo-controlled, non-inferiority trial, HIV-1-infected adults were screened and enrolled at 119 hospitals in 11 countries in North America and Europe. Participants were virally suppressed (HIV-1 RNA

U2 - 10.1016/S2352-3018(17)30031-0

DO - 10.1016/S2352-3018(17)30031-0

M3 - Article

SN - 2352-3018

VL - 4

SP - e195-e204

JO - The Lancet HIV

JF - The Lancet HIV

IS - 5

ER -